BIOMAT Database Logo BIOMAT Database Logo

Pharmacokinetics of rifabutin during atazanavir/ritonavir co-administration in HIV-infected TB patients in India. 2013

G Ramachandran, and P K Bhavani, and A K Hemanth Kumar, and R Srinivasan, and K Raja, and V Sudha, and S Venkatesh, and C Chandrasekaran, and S Swaminathan
National Institute for Research in Tuberculosis, Chetpet, Chennai, India.

METHODS Rifabutin (RBT) is reported to be as effective as and to have less inducing effect on cytochrome P450 enzymes than rifampicin against tuberculosis (TB). The optimal dose of RBT during ritonavir (RTV) co-administration remains a matter of debate. OBJECTIVE To study the pharmacokinetics of 150 mg RBT thrice weekly during concomitant atazanavir/RTV administration in human immunodeficiency virus (HIV) infected TB patients. METHODS This observational study was conducted in 16 adult HIV-infected TB patients being treated for TB with an RBT-containing regimen and an antiretroviral therapy regimen with RTV; the dose of RBT was 150 mg thrice weekly. Serial blood draws were performed at pre-dosing and at 1, 2, 4, 6, 8, 12 and 24 h after the drug was administered. Plasma RBT was estimated using high-performance liquid chromatography. CONCLUSIONS Peak RBT concentration was below the lower therapeutic limit (<0.3 μg/ml) in seven patients, while 10 patients had trough concentrations below the minimal inhibitory concentration against Mycobacterium tuberculosis (0.06 μg/ml), suggesting that the RBT dosage may be inadequate. Prospective studies in different settings are required to arrive at the proper therapeutic dose for RBT to be used during co-administration with RTV.

UI MeSH Term Description Entries
D007194 India A country in southern Asia, bordering the Arabian Sea and the Bay of Bengal, between Burma and Pakistan. The capitol is New Delhi. Republic of India
D008297 Male Males
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D009842 Oligopeptides Peptides composed of between two and twelve amino acids. Oligopeptide
D011725 Pyridines Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females

Related Publications

G Ramachandran, and P K Bhavani, and A K Hemanth Kumar, and R Srinivasan, and K Raja, and V Sudha, and S Venkatesh, and C Chandrasekaran, and S Swaminathan
Pharmacokinetics of rifabutin during atazanavir/ritonavir co-administration in HIV-infected TB patients.
January 2019, The Indian journal of tuberculosis,
G Ramachandran, and P K Bhavani, and A K Hemanth Kumar, and R Srinivasan, and K Raja, and V Sudha, and S Venkatesh, and C Chandrasekaran, and S Swaminathan
Atazanavir and atazanavir/ritonavir pharmacokinetics in HIV-infected infants, children, and adolescents.
July 2011, AIDS (London, England),
G Ramachandran, and P K Bhavani, and A K Hemanth Kumar, and R Srinivasan, and K Raja, and V Sudha, and S Venkatesh, and C Chandrasekaran, and S Swaminathan
Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers.
June 2009, The Journal of antimicrobial chemotherapy,
G Ramachandran, and P K Bhavani, and A K Hemanth Kumar, and R Srinivasan, and K Raja, and V Sudha, and S Venkatesh, and C Chandrasekaran, and S Swaminathan
Pharmacokinetics and safety of rifabutin in young HIV-infected children receiving rifabutin and lopinavir/ritonavir.
February 2015, The Journal of antimicrobial chemotherapy,
G Ramachandran, and P K Bhavani, and A K Hemanth Kumar, and R Srinivasan, and K Raja, and V Sudha, and S Venkatesh, and C Chandrasekaran, and S Swaminathan
Population pharmacokinetics and dose optimisation of ritonavir-boosted atazanavir in Thai HIV-infected patients.
March 2017, International journal of antimicrobial agents,
G Ramachandran, and P K Bhavani, and A K Hemanth Kumar, and R Srinivasan, and K Raja, and V Sudha, and S Venkatesh, and C Chandrasekaran, and S Swaminathan
Population pharmacokinetics of atazanavir/ritonavir in HIV-1-infected children and adolescents.
December 2011, British journal of clinical pharmacology,
G Ramachandran, and P K Bhavani, and A K Hemanth Kumar, and R Srinivasan, and K Raja, and V Sudha, and S Venkatesh, and C Chandrasekaran, and S Swaminathan
Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients.
July 2006, European journal of clinical pharmacology,
G Ramachandran, and P K Bhavani, and A K Hemanth Kumar, and R Srinivasan, and K Raja, and V Sudha, and S Venkatesh, and C Chandrasekaran, and S Swaminathan
Impact of nevirapine or efavirenz co-administration on ritonavir-boosted amprenavir pharmacokinetics in HIV-infected patients.
February 2008, Fundamental & clinical pharmacology,
G Ramachandran, and P K Bhavani, and A K Hemanth Kumar, and R Srinivasan, and K Raja, and V Sudha, and S Venkatesh, and C Chandrasekaran, and S Swaminathan
Pharmacokinetic interactions between rifabutin and lopinavir/ritonavir in HIV-infected patients with mycobacterial co-infection.
October 2009, The Journal of antimicrobial chemotherapy,
G Ramachandran, and P K Bhavani, and A K Hemanth Kumar, and R Srinivasan, and K Raja, and V Sudha, and S Venkatesh, and C Chandrasekaran, and S Swaminathan
Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients.
January 2007, Antiviral therapy,
Copied contents to your clipboard!